Pilot Study of Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT02209376

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:39:06.709468+00:00

Published At

2023-06-22T00:00:00+00:00

Record Updated At

2023-06-22

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Patients With Residual or Reccurent EGFRvIII+ Glioma"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2023-06-22"

protocolSection.identificationModule.nctId

"NCT02209376"

protocolSection.identificationModule.officialTitle

"Pilot Study of Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma"

protocolSection.statusModule.overallStatus

"TERMINATED"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Patients With Residual or Reccurent EGFRvIII+ Glioma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.